Drug Information Journal, Vol. 22, pp. IX–XV, 1988
Printed in the USA. All rights reserved.

0092-8615/88 $3.00 + .00
© 1988 Drug Information Association Inc.

Contents
Volume 22, 1988

Volume 22, Number 1 1988

CONTENTS

Peter H. Rheinstein	1	Milestones at FDA and DIA *Keynote Address*
Mark Novitch	7	Drug Information in the Global Village *Keynote Address*
D. H. Lawson	11	Scientific Problems in Collecting and Analysing Safety Data in Nonexperimental Studies
D. H. Lawson	19	Use of Advisory Committees, Consultants, and Academic Reviewers by Drug Regulatory Authorities
Jerome A. Halperin	25	Challenge, Opportunity, Promise, and Risk: The Pharmaceutical Industry Moving Toward the 21st Century
Daniel E. Klingler	33	Design Considerations for Microcomputer User Interfaces
Russell J. Abbott	47	Current Status of the NDA Tracking System at the FDA
Russell J. Abbott	55	Current Status of Computer-Assisted NDAs
Joel H. Dobbs	59	A Pilot Study of Electronic Submission of Periodic Reports to the FDA: Flexible Diskette Submission – Glaxo Program Development
Michael H. Dong **Charles Anello** **John P. Juergens** **Wayne M. Turner** **Alan Gelberg** **George D. Armstrong**	61	A Microcomputer-Based Data Entry System for Reporting Adverse Drug Reactions in the United States
Joel H. Dobbs	71	Exchange of Worldwide Safety Surveillance Data via an International Computer Database

Lawrence G. Mondschein	75	The Use of Facsimile Technology in a Multicenter Clinical Trial
Hans H. Lindén	87	Patient–Drug Information From an Administrative Viewpoint
G. Jones	95	Acceptance of Foreign Clinical Data
Ted M. Kirsch **Maarja Hildebrand** **Mirza Beg** **Michael J. Fox**	99	Ancillary Data Management
Kosaku Uchida	103	Acceptability of Foreign Clinical Trial Data in Japan
Michael C. Gerald	109	Proposed Guidelines for International Control of Psychoactive Substances
Michael Slater	123	Regulatory Affairs Issues in Biotechnology
Duilio Poggiolini	133	International Regulation of Drugs
Bernd Knabe	137	Acceptance of Foreign Clinical Data in Industry
G. L. Mattok	143	Premarketing Biopharmaceutical Requirements
	I	Software Survey Section: *CAMSEQ/M Molecular Modeling System* *ChemText* *GRANT TRACKER™* *AssayZap* *AUTOBIBLIO* *CLIN-TEAMS/PCS™ V1.1* *CLIN-TEAMS/DER™ V1.0* *CLIN-TEAMS™ V4.1* *CLIN-TEAMS™ V5.0 (June 1988)*

Volume 22, Number 2 1988

CONTENTS

Thomas J. Ott	149	Foreword and Acknowledgements
Richard F. Kingham	151	History of FDA Regulation of Clinical Research
Allen F. Hirsch	157	Preparation for an FDA Sponsor/Monitor Inspection
Paul W. Goebel, Jr	161	The Role of the Institutional Review Board
Jon R. Wallace	165	Regulatory Compliance in International Drug Development

Robert N. Smith	169	Does Worldwide Clinical Research Accelerate the Development of New Drugs?
Alan F. Sewell	173	Identification and Qualification of Foreign Contract Research Organizations
John J. Donahue	177	Future Trends in Quality Assurance
Thomas J. Kirsch	181	Sponsor Education of Clinical Investigators in the Clinical Research Process
Zella A. Hendon	187	Experiences with Contract Research Organizations
Thomas Honohan	193	Practical Problems in the Conduct of Non-US Studies From Which Data Will be Used for US Registration
Galen H. Neher	199	Finding and Evaluating CROs
D. P. Foster	203	Special Problems/Situations in Clinical Auditing Overseas
C. Stephen Lawrence	207	FDA Inspection of Clinical Research Sponsors and Investigators: Avoiding the Pitfalls
Thomas J. Kirsch	225	Discussion Panel: Auditing of Clinical Research: Internal and External Panel Discussion
Thomas J. Ott	239	Discussion Panel: Meet the FDA: Question and Answer Period
Daniel E. Klingler	249	Expert Systems in the Pharmaceutical Industry
Stephen J. Knoop **Daniel E. Worden**	259	The Pharmaceutical Drug Development Process: An Overview
Melvin P. Fisher	269	Achieving Consistency in International Drug Labeling
	I	Software Survey Section: *Genetics Tutorial—CompTutor Software*

Volume 22, Number 3 1988

CONTENTS

Karl E. Peace **Harvey Zimmerman**	277	Foreword: Cost-Benefit Assessment of Pharmaceutical Products

Harriet G. Tolpin	281	Overview of CBA and CEA Methods
Judith D. Bentkover	291	CBA/CEA of Pharmaceuticals: Methods and Applications
Amiram D. Vinokur	311	Application of Quality of Life and Well-Being Measurement as Input Into Cost-Effectiveness Analyses
Thi D. Dao	317	The Application of CBA to Pharmaceuticals: Going From CBA to CEA to CUA
Thomas A. Hodgson	323	Annual Costs of Illness Versus Lifetime Costs of Illness and Implications of Structural Change
Graham A. Colditz **James N. Miller** **Frederick Mosteller**	343	The Effect of Study Design on Gain in Evaluations of New Treatments in Medicine and Surgery
Herbert E. Gladen	353	Ethical Changes: Duty to Man Versus Duty to Mankind
William H. Hubregs	359	Cost-Benefit Analysis and Pricing Considerations in the Regulatory Arena
John Urquhart **Cynthia Chevalley**	363	Impact of Unrecognized Dosing Errors on the Cost and Effectiveness of Pharmaceuticals
Jeffrey P. Koplan	379	The Benefits and Costs of Immunizations Revisited
Janet D. Elashoff	385	Trial Designs to Demonstrate Cost-Benefit Claims for Antiulcer Drugs
J. Leighton Read	395	Health Outcomes Should be Viewed as an Area Under the Curve
Jeffrey P. Koplan	407	The Use of Cost-Effectiveness Analyses at a Federal Public Health Agency
Charles M. Wylie	411	Hospital Data on Duodenal Ulcers: A Base for the Cost-Benefit Assessment of Antiulcer Drugs
Sanford H. Roth	419	Antiulcer Therapy in NSAID Gastropathy: A Rheumatologist's Perspective
Gary R. Cutter	425	Cost-Effectiveness of Prevention, Intervention, and Therapeutic Strategies in Coronary Artery Disease
Frank Lanza **Karl E. Peace** **Harvey Zimmerman** **Brian Dickson**	449	Cost-Effectiveness of Cimetidine and Misoprostol in Peptic Ulcer Disease

John M. Eisenberg
Henry Glick
Harris Koffer 459 Assessing the Hidden Cost of Antibiotic Therapy for Hospitalized Patients

Robert S. Stern 471 Childhood Sunscreen Use: Factors Affecting Cost-Effectiveness

Sanford H. Roth 477 NSAIDs: Risk-Benefit Versus Cost-Benefit

A. Lewis Kolodny 483 Cost-Benefit Assessment of Salicylates and NSAIDs in Treating Arthritic Disease

I Software Survey Section:
DOCUMENT MANAGER
EVENT TRACKER

Volume 22, Number 4 1988

CONTENTS

K. Shirakawa
K. Ozasa
K. Kawai 493 Natural History and Cost-Benefit of Drug Therapy for Peptic Ulcers

Karl E. Peace
Thomas D. Cannon 499 Biotechnology and the Biostatistician

C. Everett Koop 515 Remarks

F. Randy Vogenberg 521 Strategic Planning for Drug Information Services

Albert Weissman 527 On the Verb Tense to be Used in the Investigator's Brochure

Dennis F. Thompson
Dwight Vance
Joanne C. Callard
Clinton M. Thompson, Jr 531 Accessing the Lay Drug Literature: A Comparison of DIALOG, BRS, and WILSONLINE

William B. Stason 539 Economics of Managing Hypertension

Linda M. Ettorre 547 Retrospective Validation of Existing Computer Systems

Stephen A. Osiobe 553 Physicians' and Pharmacists' Drug Information Sources in Nigeria

Michael R. Hamrell 565 A PC-based Information Tracking System for Submissions at the FDA

Philippe O. Lejeune	569	Laptops for Data Entry by Investigators
Maura A. Kraynak **Karen L. Kier**	573	Selected References on Adverse Drug Reaction Reporting
P. Ambroise-Thomas **B. Uzzan** **A. Chicoye** **F. Lacombe**	581	French Context for Clinical Evaluation of Drugs: Network of Clinical Pharmacology and Good Clinical Practices
Douglas E. May	587	How to Conduct a Needs Assessment
Richard W. Boss	599	Overview of Information Management Systems
Deanne E. Knapp **Zollie A. Perry**	607	Trend of Spontaneous Reports Containing Selected Adverse Drug/Biologic Reactions: 1970–1986
Jan Venulet	609	Early Recognition of Potential Drug Safety Problems
Marion J. Finkel	619	More Similarities Than Differences
	I	Software Survey Section: *The TOPKAT Program* *HZI Brain Function Monitoring System* *DLB Clinical Trials Management System* *DLB Adverse Event Monitoring System*
	VII	Volume 22 Contents and Author Index